TLR3 and neoplasm: TLR3 agonist poly-ICIC and TLR7/8 agonist Resiquimod have been combined with tumor vaccines in the treatment of melanoma (NCT02126579) and advanced tumors refractory to conventional treatment (NCT00948961).